Holen Sie sich die Stockscreener-App
157.65
1.16%
-1.43
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Ligand Pharmaceuticals Inc Aktie (LGND) Neueste Nachrichten
Ligand Q1 2025 slides: Revenue surges 46%, strategic Pelthos merger announced - Investing.com
Ligand to Participate in September Investor Conferences | LGND Stock News - GuruFocus
Ligand Pharmaceuticals to Participate in Upcoming Investor Conferences in September 2025 - Quiver Quantitative
Ligand to Participate in September Investor Conferences - Yahoo Finance
Published on: 2025-08-18 01:20:46 - sundaytimes.kr
Ligand Pharmaceuticals to offer $400M convertible senior notes in private placement - MSN
Why Ligand Pharmaceuticals Incorporated stock attracts strong analyst attentionJuly 2025 News Drivers & Daily Growth Stock Tips - beatles.ru
What to do if you’re stuck in Ligand Pharmaceuticals IncorporatedDividend Hike & AI Forecast for Swing Trade Picks - Newser
Ligand Pharmaceuticals Incorporated Shows Early Signs of Technical Strength2025 Trading Recap & Free High Accuracy Swing Entry Alerts - sundaytimes.kr
Ligand Pharmaceuticals raises $400mln through convertible senior notes offering. - AInvest
Ligand Pharma Completes $460M Convertible Notes Offering - TipRanks
Ligand Pharmaceuticals completes $460 million convertible notes offering By Investing.com - Investing.com Canada
Ligand Announces Closing of Convertible Senior Notes Offering - Yahoo Finance
Detecting support and resistance levels for Ligand Pharmaceuticals IncorporatedWeekly Market Summary & Expert Approved Momentum Ideas - Newser
US Bancorp DE Purchases 3,301 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $185.00 - MarketBeat
Ligand Pharmaceuticals shares rise 3.65% intraday after pricing $400 million convertible senior notes offering. - AInvest
Ligand's $400M Convertible Notes Offering: A Strategic Move for M&A-Driven Growth and Shareholder Value - AInvest
Ligand Pharmaceuticals Stock (LGND) Opinions on $400M Convertible Notes Offering - Quiver Quantitative
Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates - Yahoo Finance
Ligand Prices $400 Million Convertible Senior Notes Offering - MarketScreener
Ligand Pharmaceuticals Experiences Strong Q2 Earnings with Robust Revenue Growth, Successful Mergers and Investments, and Raised Financial Guidance. - AInvest
Ligand Pharmaceuticals Prices Offering Of $400 Mln Of Senior Notes - Nasdaq
Analysts Bullish on Insmed and Ligand Pharma: Strong Buy Ratings and High Price Targets - AInvest
Ligand Pharmaceuticals Secures $400M in Convertible Debt Offering - AInvest
Ligand Pharmaceuticals' Convertible Notes Offering: A Strategic Move for Capital Optimization and Growth - AInvest
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering | LGND Stock News - GuruFocus
Ligand Pharmaceuticals prices $400 million convertible notes offering By Investing.com - Investing.com Canada
Ligand's Convertible Notes Offering: Balancing Dilution Risks and Strategic Flexibility in Biopharma Financing - AInvest
Ligand Pharmaceuticals Prices $400 Million Convertible Senior Notes Due 2030 - Quiver Quantitative
Ligand Secures $400M Convertible Note Deal: Key Terms Reveal 0.75% Rate and $15M Share Buyback - Stock Titan
Ligand prices $400 million convertible senior notes offering - MarketScreener
Ligand Pharmaceuticals Prices $400M Convertible Senior Notes Offering - AInvest
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering - MarketScreener
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering - GlobeNewswire Inc.
LGNDLigand Pharma Latest Stock News & Market Updates - Stock Titan
Ligand Pharmaceuticals Inc. Reports Strong Q2 Earnings - TipRanks
LGND: Getting In Tune with MedTech - Zacks Small Cap Research
Ligand Pharmaceuticals Plans $400 Million Convertible Senior Notes Offering - MarketScreener
Ligand Pharma Proposes Private Offering Of $400 Mln Of Sr. Notes - Nasdaq
Ligand Pharmaceuticals shares fall 4.06% premarket after announcing a $400 million convertible senior notes offering. - AInvest
Ligand Announces $400M Convertible Senior Notes Offering Due 2030. - AInvest
Ligand Pharmaceuticals plans $400 million convertible notes offering By Investing.com - Investing.com Canada
Ligand Pharmaceuticals to Offer $400mln Convertible Senior Notes Due 2030. - AInvest
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 - MarketScreener
Ligand Launches Major $400M Convertible Notes Deal with Strategic Share Buyback Plan - Stock Titan
Analyzing Ligand Pharmaceuticals Incorporated with risk reward ratio chartsMonthly Long-Term Market Recap and Summary - Newser
Ligand's Q2 2025: Unraveling Contradictions in Pelthos Launch, Deal Strategies, and Market Dynamics - AInvest
Will Ligand Pharmaceuticals Incorporated Recover After Recent DeclineStable Entry High Return Opportunities in Focus - beatles.ru
Royal Bank Of Canada Forecasts Strong Price Appreciation for Ligand Pharmaceuticals (NASDAQ:LGND) Stock - Defense World
A Quick Look at Today's Ratings for Ligand Pharmaceuticals(LGND.US), With a Forecast Between $157 to $185 - 富途牛牛
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2025 Earnings Call Transcript - Insider Monkey
Published on: 2025-08-09 07:41:08 - beatles.ru
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Rating Upgraded by Wall Street Zen - Defense World
Ligand Pharmaceuticals shares rise 3.05% intraday after Q2 2025 earnings call. - AInvest
Ligand: RBC Raises PT to $185, Maintains Outperform Rating - AInvest
Ligand Pharma stock price target raised to $185 from $155 at RBC Capital - Investing.com Canada
Ligand Pharmaceuticals Among 3 Stocks Possibly Trading Below Intrinsic Value Estimates - Yahoo Finance
Ligand Pharmaceuticals Q2 2025 Earnings Call Highlights: Robust Royalty Growth and Strategic Partnerships - AInvest
Ligand Pharmaceuticals Raises FY25 EPS and Revenue Outlook, Boosts EPS View to $6.70-$7.00 and Revenue View to $200M-$225M. - AInvest
Ligand Pharma Receives Buy Rating from Joseph Pantginis Due to Strong Financial Performance and Strategic Positioning. - AInvest
Ligand Pharmaceuticals Reports Q2 EPS and Revenue Above Consensus, Raises 2025 Guidance - AInvest
Ligand Pharmaceuticals Inc (LGND) Q2 2025 Earnings Call Highlights: Robust Royalty Growth and ... By GuruFocus - Investing.com Canada
Ligand Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Ligand Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Ligand Pharmaceuticals Raises 2025 Revenue Guidance to $225M Amid Royalty Portfolio Momentum - AInvest
Transcript : Ligand Pharmaceuticals Incorporated, Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Pelthos Therapeutics shares rise 2.00% after-hours following Ligand Pharmaceuticals' Q2 revenue increase of 15%. - AInvest
Ligand Pharma stock price target raised to $167 by Oppenheimer on strong royalty growth - Investing.com Canada
Earnings call transcript: Ligand Pharmaceuticals Q2 2025 beats forecasts, stock rises - Investing.com Canada
Ligand Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Ligand: Q2 Earnings Snapshot - San Francisco Chronicle
1.14%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):